Yee Chung Cheng, MD
Associate Professor of Medicine
Dr. Yee Chung Cheng has joined the Medial College of Wisconsin since 2004. He is currently the Associate Professor of Medicine in the Division of Hematology and Oncology, and the associate program director of the Hematology and Oncology Fellowship program. Dr. Cheng practices at both Froedtert Hospital/Clinical Cancer Center where he specializes in breast cancer, and at Clement J. Zablocki VA Medical Center where he serves as the Section Chief of Hematology and Oncology.
Dr. Cheng has completed his Hematology and Oncology training at Baylor College of Medicine, Houston, and also Blood and Marrow Transplantation training at the University of Texas M. D. Anderson Cancer Center, Houston. His clinical research interest is in the potential use of hematopoietic stem cell transplantation in solid tumors particularly in breast cancer.
1. Cheng YC, Ueno NT. Non-myeloablative Allogeneic Peripheral Blood Progenitor Cell Transplantation for Metastatic Breast Cancer and Metastatic Renal Cell Carcinoma: The M. D. Anderson Cancer Center Experience. Haematologica 87 (supplement number 6): 6-9, June 2002.
2. Cheng YC, Ueno NT. Allogeneic Hematopoietic Stem-Cell Transplantation for Solid Tumors in the United States: A Review. Nippon Rinsho (Japanese Journal of Clinical Medicine) 61 (9): 1619-1634, Sept 2003.
3. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, IF Khouri, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid Induction of Complete Donor Chimerism by the Use of a Reduced-Intensity Conditioning Regimen Composed of Fludarabine and Melphalan in Allogeneic Stem Cell Transplantation for Metastatic Breast Cancer and Renal Cell Carcinoma. Blood 102 (10): 3829-3836, November 15, 2003.
4. Cheng YC, Rondón G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The Use of High-Dose Cyclophosphamide, Carmustine, and Thiotepa plus Autologous Hematopoietic Stem-Cell Transplantation as Consolidation Therapy for High-Risk Primary Breast Cancer after Primary Surgery or Neoadjuvant Chemotherapy. Biology of Blood and Marrow Transplantation 10 (11): 794-804, November 2004.
5. Cheng YC, Tannir N, Champlin RE, Ueno TN. Allogeneic Hematopoietic Stem-Cell Transplantation for Metastatic Renal Cell Carcinoma. Kidney Cancer Journal 3 (3): 11-20, 2005
6. Cheng YC, Saliba RM, Rondón G, Sergio GA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low Prevalence of Premature Ovarian Failure in Women Given Reduced-Intensity Conditioning Regimens for Hematopoietic Stem-Cell Transplantation. Haematologica 90 (12): 1725-1726, December 2005
7. Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT. Interleukin-2 and Granulocyte-Macrophage–Colony Stimulating Factor Immunomodulation with High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Patients with Metastatic Breast Cancer. International Journal of Hematology 90 (5): 627-634, December 2009.
8. Cheng YC, Ueno NT. Is High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer Patients a Done Deal? Women’s Health 6 (4): 481-485, July 2010
9. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of Granulocyte-Macrophage–Colony Stimulating Factor to Trastuzumab Stabilizes Diseases in Patients with Trastuzumab-Resistant, HER2-Positive Metastatic Breast Cancer. British Journal of Cancer 103 (9): 1331-1334, October 26, 2010.
10. Cheng YC, Ueno NT. Improvement of Survival and Prospect of Cure in Patients with Metastatic Breast Cancer. Breast Cancer (in press).
Best Doctors® and the star-in-cross logo are registered trademarks of Best Doctors, Inc. in the United States and other countries.